Comparison of Hormonal Therapy: Mediating Hot Flashes Tapering Regimens for Mediating Hot Flashes

A Comparison of Hormonal Therapy:

Tapering Regimens for Mediating Hot Flashes

Clinicians have been asking for years whether a tapering dose of HT would make a difference
in the frequency and severity of vasomotor symptoms after menopausal women stop HT therapy.
This planned randomized, placebo-controlled trial (RCT) seeks to evaluate whether there is a
difference in the proportion of women who report a worsening severity of their hot flashes
between three tapering schedules for one accepted HT/ET regimen. Secondarily, we hope to
evaluate whether there is a difference in the frequency (number of occurrences per week),
severity (defined as a subjective scale mild, moderate, or severe), and "Severity Index"
(SI, equaling the product of both) of hot flashes between three tapering schedules for one
accepted HT/ET regimen.

All participants will be randomized to one of the three arms (taper arm, placebo arm, and
"cold turkey" arm). Each patient's gynecologist will be aware of the patient's involvement
in the study and will assist by providing baseline safety information. All patients will be
taken off their current HT/ET regimen and will be placed on study medication (1 mg of
Estradiol PO every day for 8 weeks, "stabilization" phase). After the 8-week stabilization
period, all participants will begin the therapy corresponding to the arm to which they were
randomized. Each patient in the taper or placebo arm will take one capsule per day. The
patients in the "cold turkey" arm will discontinued acutely after the stabilization.

The patients will keep a diary of the number and frequency of symptoms during the study.
Patients will be contacted by phone to confirm that they are completing their diaries and
that they have not developed side effects or complications that could force their
discontinuation from the study.

Patients will be followed for several additional weeks, after discontinuation from treatment
or placebo, to monitor for symptoms. At the end of the study, our coordinator will contact
the patient to assure that Medroxyprogesterone acetate, MPA, was taken properly by those
women who have a uterus. They will also confirm that no other symptoms, complications, or
questions have arisen. At that time, they will be able to return to their prior therapy as
deemed appropriate by them and their physician.

Patients will be recruited by invitation upon presenting for care to their physician. With
invitations at recruitment, all patients will be given a study form. Reasons for
ineligibility or refusal will be noted. After expressing interest, the physician or practice
of record will sign a form acknowledging that their patient has had an annual physical exam
(including pelvic exam) within the last 12 months and that a mammogram has been reported as
negative (BIRADS I or II) within the last 24 months. An appointment will be made with one of
our study personnel or coordinators. The patient will bring the signed form to this visit.
At this enrollment / consent visit, their eligibility criteria will be reviewed. All
patients will sign the informed consent, and be randomized to a group.

Inclusion Criteria:

- Female.

- ages 35-70, inclusive.

- Postmenopausal (Natural or surgical: see definitions).

- Currently on HT/ET for at least 6 months for vasomotor symptomatology.

- Vasomotor symptoms are currently controlled on medication .

- An annual physical & pelvic exam has been performed within the last 12mo

- The patient has had a normal mammogram(BIRADS I/II) within the last 24mo

Exclusion Criteria:

- Males

- Hypertension, defined as either SBP >140 mmHg or DBP >90 mmHg

- Lack of compliance (willingness to adhere to protocol)

- Inability or unwillingness to swallow pills

- Patients with any contraindications to HT/ET